Valeant Pharmaceuticals (TSX: VRX) says it will price its injectable biologic Siliq (brodalumab) at the bottom end of the market.
The Canadian firm, which has suffered from a slew of negative media stories related to its pricing practices, says the psoriasis treatment will be available for $3,500 per month.
The price was approved by the company’s Patient Access and Pricing Committee (PAPC), a body set up by the company in an attempt to dispel criticism over price gouging.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze